La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Webus International a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Webus International..

Webus International (NASDAQ:WETO) Azioni, Catena delle Opzioni

Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.

Webus International Limited - Ordinary Shares

Webus International Ltd

Wetouch Technology Inc

Shares of Chinese electric vehicle (EV) maker XPeng Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) surged 7.7% to $21.15 Monday morning following news that the U.S. and China reached a temporary truce in their ongoing trade dispute, agreeing to significantly roll back tariffs on <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">most goods for 90 days</a>.
What To Know: XPeng, an EV manufacturer based in Guangzhou, stands to benefit directly from the <a href="https://www.benzinga.com/topic/tariffs">tariff</a> reduction. The company has been aggressively expanding its footprint in Europe and exploring entry into the North American market.
With tariffs now lowered from 125% to just 10% on most categories, XPeng's cost structure for potential U.S. exports and imported U.S. components likely improves considerably.
Moreover, China's suspension of non-tariff countermeasures, including sanctions and export restrictions on high-tech materials, could ease XPeng's access to advanced semiconductors and batteries, critical to its XNGP autonomous driving platform and upcoming G6 and X9 models.
The easing of geopolitical tensions could also boost investor confidence in XPeng's international strategy and alleviates risks tied to supply chain disruptions and trade barriers.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/05/45327340/3-best-energy-stocks-to-buy-right-now">3 Best Energy Stocks To Buy Right Now</a>
<h2 class="wp-block-heading">How To Buy XPEV Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in XPeng&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XPEV has a 52-week high of $27.16 and a 52-week low of $6.60.

News

XPEV

XPeng (XPEV) Stock Surges On US–China Tariff Easing: What's Going On?

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from the same period last year.

Earnings

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

Jianzhi Education Technology Group Company Limited ("Jianzhi") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>), a leading provider of digital educational content in China, today announced it had partnered with China Telecom, one of the world's largest and most influential integrated communications and technology providers. This major collaboration represents a critical step forward in integrating Jianzhi's robust education platforms into China Telecom's expansive cloud center infrastructure.
Following extensive negotiations between the two organizations, this landmark collaboration aims to reshape the future of education by embedding cutting-edge AI-generated content (AIGC) and digital human technologies into every facet of the learning experience.
China Telecom, a Fortune Global 500 company with over 425 million mobile subscribers and operating revenues amounting to US$72.5 billion in 2024, brings immense infrastructure strength, technical support, and national reach to the project. By aligning with&nbsp;Jianzhi, China Telecom will further extend its strategic presence in the digital education space through seamless cloud-based delivery. Jianzhi's cloud-ready educational content and platforms will support the joint development of new cloud-native applications and services tailored to the needs of learners and institutions nationwide.

Jianzhi Education Technology Announces It Had Partnered With China Telecom, Collaboration Aims To Reshape The Future Of Education By Embedding Cutting-Edge AI-Generated Content And Digital Human Technologies Into The Learning Experience

Earnings Beats

CORRECTION: NRG Energy Q1 Adj. EPS $2.62 Beats $1.49 Estimate, Sales $8.59B Beat $7.83B Estimate

WIIM

RMTI

Rockwell Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

MEGL

Magic Empire Global shares are trading lower after the company announced it filed a prospectus for the offer and sale of up to 15 million shares.

Guggenheim analyst Curry Baker maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $61 to $60.

Price Target

Analyst Ratings

DKNG

Guggenheim Maintains Buy on DraftKings, Lowers Price Target to $60

Management

NWBI

Northwest Bancshares Announces Timothy B. Fannin Has Stepped Down As Board Chair, And Has Been Succeeded By Vice Chair Timothy M. Hunter

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Richard Close downgraded DocGo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) from Buy to Hold and lowered the price target from $5 to $1.45. DocGo shares closed at $1.40 on Friday. <a href="https://www.benzinga.com/quote/dcgo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research analyst Michael Petusky downgraded the rating for ModivCare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) from Outperform to Market Perform. ModivCare shares closed at $1.17 on Friday. <a href="https://www.benzinga.com/quote/modv/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ekaterina Knyazkova downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and cut the price target from $45 to $30. Amphastar Pharma shares closed at $24.11 on Friday. <a href="https://www.benzinga.com/quote/amph/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Zhihan Ma downgraded the rating for Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) from Market Perform to Underperform and lowered the price target from $97 to $82. Target shares closed at $96.40 on Friday. <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Stephen Laszczyk downgraded Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Buy to Neutral and slashed the price target from $35 to $28. Warner Music shares closed at $27.36 on Friday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TGT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png" alt="" class="wp-image-911928" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Trading Ideas

AMPH

DCGO

MODV

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Superior Industries International shares are trading lower after the company reported worse-than-expected Q1 EPS results and announced it is withdrawing its FY25 guidance.

Inter &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTR#NASDAQ">INTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.12 by 8.33 percent. This is a 22.22 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $313.81 million which missed the analyst consensus estimate of $327.02 million by 4.04 percent. This is a 10.88 percent increase over sales of $283.02 million the same period last year.

Earnings Misses

INTR

Inter & Co Q1 GAAP EPS $0.11 Misses $0.12 Estimate, Sales $313.81M Miss $327.02M Estimate

In the face of ongoing trade tensions,&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly contemplating raising the prices for its forthcoming fall iPhone models, while also planning to introduce new features and design changes.
What Happened: The iPhone maker is planning a price hike but is keen to dispel any notion that a possible price increase is tied to U.S. tariffs on Chinese goods, where most of its devices are assembled, according to a <a href="https://www.wsj.com/tech/apple-iphone-price-increase-2eaebb14">report</a> by The Wall Street Journal on Monday.
Facing supply chain pressures, Apple is considering raising iPhone prices to protect profits, while seeking non-tariff reasons to justify the hike, though new feature details remain unclear. Notably, the company is preparing to launch new iPhones this fall, which will include design updates such as an ultrathin profile.
CEO Tim Cook has been navigating the U.S.-China trade tensions, which threaten Apple's supply chain. In response, he has increased inventory levels and moved some U.S.-bound manufacturing to India. However, production of Apple's high-end models like the Pro and Pro Max will largely remain in Chinese factories, as India's infrastructure and technical capacity are not yet advanced enough to support large-scale production on par with China's current capabilities, sources told the publication.
Apple is also exploring the possibility of shifting some iPhone production to the U.S., a move that could take several years. In the meantime, its shift toward manufacturing smartphones in India for export to the U.S. is expected to gain momentum.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45343504/judge-halts-arizona-land-transfer-to-rio-tinto-citing-native-appeal" target="_blank" rel="noreferrer noopener">Judge Halts Arizona Land Transfer To Rio Tinto Citing Native Appeal</a>
Why It Matters: Apple&#8217;s potential price hike comes amid a series of strategic moves and product innovations. Earlier in May, Apple&#8217;s CEO, Tim Cook, discussed the possibility of <a href="https://www.benzinga.com/markets/25/05/45162929/tim-cook-tells-commerce-secretary-lutnick-how-apple-could-bring-iphone-manufacturing-to-us">relocating iPhone</a> production to the U.S. with U.S. Commerce Secretary Howard Lutnick. This was followed by the news of Apple bracing for a $900 million <a href="https://www.benzinga.com/markets/25/05/45185355/apple-braces-for-900-million-tariff-impact-tim-cook-discusses-potential-iphone-manufacturing-shift-to-us-with-lutnick-and-more-this-week-in-appleverse">tariff impact</a>, as revealed by Cook during the company&#8217;s fiscal second-quarter earnings call.
Notably, Apple is reportedly planning a <a href="https://www.benzinga.com/tech/25/05/45338324/apples-2027-vision-foldable-iphones-smart-glasses-and-ai-innovations">significant year </a>in 2027, with plans to introduce a range of innovative devices and features, including a foldable iPhone and smart glasses. These developments highlight Apple&#8217;s ongoing efforts to navigate trade tensions while maintaining its commitment to innovation and customer satisfaction.
Despite these strategies, Apple may still find it challenging to counterbalance China tariff costs solely through supplier savings, potentially affecting its profit margin unless it can increase prices. However, executives are wary about attributing price increases to tariffs, after the White House slammed Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), displaying tariffs beside its product prices and calling it a &#8216;hostile act&#8217;.
Apple holds a momentum rating of 49.76% and a quality rating of 82.46%, according to&nbsp;<a href="https://www.benzinga.com/quote/AAPL" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Apple stock has declined 18.59% during the year-to-date period.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45338404/charlie-mungers-financial-success-advice-i-avoided-standard-ways-of-failing-because-my-game-in-life-was-always-to-avoid-all-standard-ways-of-failing" target="_blank" rel="noreferrer noopener">Charlie Munger&#8217;s Financial Success Advice: &#8216;I Avoided Standard Ways Of Failing, Because My Game in Life Was Always To Avoid All Standard Ways of Failing&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

General

AAPL

AMZN

Apple May Hike iPhone Prices This Fall, Steering Clear Of Tariff Blame: Report

CTMX

CytomX Therapeutics shares are trading higher. The company announced a $100 million offering of 76.9 million shares at $1.30 per share.

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya&nbsp;(somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short stature (ISS) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">under one trial protocol</a>.
In REAL8, pre-pubertal children with NS, TS, or ISS were randomized to receive either once-weekly Sogroya&nbsp;(somapacitan) 0.24 mg/kg/week or once-daily somatropin 0.050 mg/kg/day.
Children born SGA were <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916003" rel="noreferrer noopener">randomized</a> to receive either somapacitan 0.24 mg/kg/week, a low dose of somatropin 0.035 mg/kg/day, or a high dose of somatropin 0.067 mg/kg/day.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin&nbsp;(somatropin) in improving yearly growth rate (as measured by height velocity or HV at Week 52).
In addition, once-weekly Sogroya was superior to daily growth hormone in children with NS and to lower doses of daily growth hormone in children born SGA.
REAL8 data showed that Sogroya&nbsp;was well-tolerated, with no safety or tolerability issues identified compared to once-daily growth hormone.
Results from the Turner syndrome (TS) sub-study of REAL8 will be available later this year.
The REAL8 trial achieved its primary endpoints for the first three sub-studies, demonstrating that once-weekly Sogroya&nbsp;was non-inferior to once-daily growth hormone treatment at Week 52 across the three indications presented:
<ul class="wp-block-list">
<li>In children born SGA, Sogroya&nbsp;demonstrated superior estimated mean HV when compared with a lower dose (0.035 mg/kg/day) of somatropin (11.0 vs 9.4 cm/year) and non-inferior estimated mean HV when compared with a higher dose (0.067 mg/kg/day) of somatropin (11.0 vs 11.1 cm/year).</li>
<li>Sogroya&nbsp;demonstrated superior estimated mean HV in children with NS compared with somatropin (10.4 vs 9.2 cm/year).</li>
<li>Sogroya&nbsp;demonstrated non-inferior estimated mean HV in children with ISS compared with daily somatropin (10.5 vs 10.5 cm/year).</li>
<li>In April 2025, based on the data from REAL8 and REAL9, the three indications (SGA, NS, and ISS) were submitted for regulatory review in both the EU and the U.S.</li>
</ul>
Price Action: NVO stock is down 3.00% to $63.80 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path" target="_blank" rel="noreferrer noopener">Shopify Shows Strong Global Momentum, But Guidance Raises Questions On Profitability Path</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

Movers

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Guggenheim analyst Debjit Chattopadhyay maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $55 to $45.

NTLA

Guggenheim Maintains Buy on Intellia Therapeutics, Lowers Price Target to $45

New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) (the "Company") is rescheduling the announcement of its financial results for the first quarter of 2025 to Wednesday, May 14th, 2025 at 4:00 P.M. Eastern Time to announce the closing of the Jamaica transaction, and announce an update to the use of proceeds. A copy of the press release and an earnings supplement will be posted to the Investors section of the Company's website, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.newfortressenergy.com&amp;esheet=54253060&amp;newsitemid=20250512039219&amp;lan=en-US&amp;anchor=www.newfortressenergy.com&amp;index=1&amp;md5=e3938874f7198884392d06c505510a99">www.newfortressenergy.com</a>.
The Company will hold a conference call on Wednesday, May 14th, 2025 at 4:30 P.M. Eastern Time. The conference call may be accessed by dialing (888) 256-1007 (toll-free from within the U.S.) or +1 (323) 701-0225 (from outside of the U.S.) fifteen minutes prior to the scheduled start of the call; please reference "NFE First-Quarter 2025 Earnings Call" or conference code 8378656.

New Fortress Energy Reschedules Q1 2025 Earnings Release And Conference Call To May 14, 2025

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) with a Buy and maintains $10 price target.

TVGN

D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

GD Culture Group shares are trading higher after the company announced a $300 million stock purchase agreement to support its crypto treasury expansion.

Mitsubishi Estate Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MITEY#OTC">MITEY</a>) reported quarterly earnings of $0.44 per share. This is a 8.33 percent decrease over earnings of $0.48 per share from the same period last year. The company reported $3.49 billion in sales this quarter. This is a 10.47 percent decrease over sales of $3.90 billion the same period last year.

MITEY

Mitsubishi Estate Co Q4 EPS $0.44 Down From $0.48 YoY, Sales $3.49B Down From $3.90B YoY

<ul>
<li>TSLA</li>
<li>GLD</li>
<li>NVDA</li>
<li>BULL</li>
<li>GOOGL</li>
<li>GOOG</li>
<li>QQQ</li>
<li>AAPL</li>
<li>AMZN</li>
<li>MSTR</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BULL

GOOG

GOOGL

MSTR

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 12, 2025 (Via Swaggy Stocks)

Press Releases

Webus International Limited Announces Pricing of Initial Public Offering and Listing on the Nasdaq Capital Market

Webus International Limited Announces Closing of Initial Public Offering

Webus International Limited CEO Nan Zheng Shares Post-IPO Progress and Strategies

Webus International Limited Announces Strategic Expansion into Japan with New Osaka Subsidiary

Comments

Webus International

Webus International (WETO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO